By analyzing existing basic indicators between Tenax Therapeutics and WXIBF, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in WXIBF with a short position in Tenax Therapeutics. Check out our
pair correlation module for more information.
Let's begin by analyzing the assets. One of the ways to look at asset utilization of Tenax is to check how much profit was generated for every dollar of assets it reports. Tenax Therapeutics has a negative utilization of assets of -73.4 %, losing $0.73 for each dollar of assets held by the company. Inadequate asset utilization indicates the company is being less effective with each dollar of assets it has. In other words, asset utilization of Tenax Therapeutics shows how discouraging it operates for each dollar spent on its assets.
Out of tens of thousands of stocks, funds, and ETFs that trade on global exchanges each represent an individual company which you can analyze using comparative analysis. To determine which one of the two entities, such as Tenax or Neurobo is a better fit for your portfolio, analyzing a few basic fundamental indicators is a good first step.
How important is Tenax Therapeutics's Liquidity
Tenax Therapeutics
financial leverage refers to using borrowed capital as a funding source to finance Tenax Therapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Tenax Therapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Tenax Therapeutics' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Tenax Therapeutics' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between Tenax Therapeutics's total debt and its cash.
Correlation Between Tenax and Neurobo Pharmaceuticals
In general, Stock analysis is a method for investors and traders to make individual buying and selling decisions. Stock correlation analysis is also essential because it can help investors realize that they may not be as diversified as they think. Risk management strategies are usually required to make sure all portfolios are properly aligned against their risk tolerance level. You can consider holding Tenax Therapeutics together with similar or unrelated positions with a negative correlation. For example, you can also add Neurobo Pharmaceuticals to your portfolio. If Neurobo Pharmaceuticals is not perfectly correlated to Tenax Therapeutics it will diversify some of the market risks out of the positively correlated stocks in your portfolio. However, the disadvantage of this sort of hedging is that it can potentially affect your investment returns throughout market cycles. When Tenax Therapeutics, for example, performs excellent and delivers stable returns, the negatively correlated position you locked in as a hedge may drag your returns down.
Are you currently holding both Tenax Therapeutics and Neurobo Pharmaceuticals in your portfolio? Please note if you are using this as a pair-trade strategy between Tenax Therapeutics and Neurobo Pharmaceuticals, watch out for correlation discrepancy over time. Relying on the historical price correlations and assuming that it will not change may lead to short-term losses. Please check
pair correlation details between TENX and NRBO for more information.
Breaking it down a bit more
Cash and Equivalents Breakdown
Lets now check Tenax Therapeutics cash and equivalents. In accordance with the recently published financial statements, Tenax Therapeutics has 8.71
M in Cash and Equivalents. This is 98.94% lower than that of the Healthcare sector and 98.05% lower than that of the
Biotechnology industry. The cash and equivalents for all United States stocks is 99.68% higher than that of Tenax Therapeutics. As for WUXI BIOLOGICS we see cash and equivalents of 664.54
M, which is 48.63% higher than that of the Biotechnology
| Sector447.1 M | WXIBF664.5 M |
| TENX | 8.71 Million | 0.78 |
| Sector | 447.12 Million | 39.91 |
| WXIBF | 664.54 Million | 59.31 |
Will Tenax continue to rise?
Mean deviation is down to 4.1. It may suggest a possible volatility slide. Tenax Therapeutics is displaying above-average volatility over the selected time horizon. Investors should scrutinize Tenax Therapeutics independently to ensure intended market timing strategies are aligned with expectations about Tenax Therapeutics volatility. Tenax Therapeutics is a potential penny stock. Although Tenax Therapeutics may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Tenax Therapeutics. We encourage investors to look for the signals such us email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on this equity instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of an artificial hype usually unable to maintain its increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.
While some other companies in the biotechnology industry are either recovering or due for a correction, Tenax Therapeutics may not be performing as strong as the other in terms of long-term growth potentials. The inconsistency in the assessment between current Tenax valuation and our trade advice on Tenax Therapeutics is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Tenax Therapeutics.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Tenax Therapeutics. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
[email protected]
